$348.9M
+$348.9M this year1 filing since 2026 · latest Equity filed
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering next-generation cancer therapeutics. The company utilizes its proprietary biologics platform to create treatments that selectively target the tumor microenvironment. Its primary goal is to advance its pipeline candidates through clinical trials and eventually commercialize them to treat various forms of cancer.
What sets it apart
The company's competitive advantage lies in its proprietary Tumor Microenvironment Activated Biologics (TMAB) platform. This platform is designed to generate therapeutics that can selectively disable immunosuppressive signals or activate immunostimulatory signals directly within the tumor, potentially improving efficacy and reducing side effects.
Acquired through the acquisition of Faeth Therapeutics, PIKTOR is Sensei's lead clinical program. It is an investigational multi-node inhibitor that targets the PI3K/AKT/mTOR cellular pathway, a critical pathway involved in cancer cell growth and survival. The company is developing it for the treatment of endometrial and breast cancer.
